We have currently upgraded our long-term recommendation on Rite Aid Corporation (RAD) to Neutral from Underperform. Headquartered in Camp Hill, Pennsylvania, Rite Aid is the third largest retail drugstore in the U.S. based on revenues and number of stores. With 4,714 stores, the company operates in 31 states across the country and in the District of Columbia.
Recent trend in the U.S. is witnessing a growing demand for generic drugs. Generic (non-brand) drugs are less expensive but generate higher gross margin. The company is expected to expand its generic drug portfolio in order to boost its top-line as well as market share. Besides, Rite Aid has an edge over its competitors as it is the third largest retail drugstore in the U.S.
Moreover, strong top-line performance and lower operating expenses boosted Rite Aid to post a better second-quarter 2012 results.The quarterly loss of 11 cents per share not only improved from the prior-year loss of 23 cents, but also outpaced the Zacks Consensus Estimate loss of 18 cents.
The company also registered a marginal revenue growth of 1.8% from the prior-year period. Consequently, the company now expects net loss to be in the range of 40 cents to 56 cents per share, instead of 42 cents to 64 cents forecasted earlier.
Further, the company is in the process of various cost cutting initiatives including centralized indirect procurement of drugs, administrative headcounts requirement, reducing supply chain costs, reducing debt, etc. which will certainly benefit the company to improve its bottom-line.
However, in the United States, pharmacy sales growth has slowed down due to longer FDA approval process, drug safety concern, loss of individual health insurance resulting from unemployment and an increase in the use of non-brand drugs, which are less expensive but generate higher gross margin. Due to these factors, the company's same-store-sales are expected to remain weak. The company has reported loss for the last fourteen consecutive quarters.
Additionally, Rite Aid is a highly leveraged company (with approximately 162% debt-to-capitalization ratio), limiting cash flow availability and its ability to obtain additional financing. The debt burden from the Brooks Eckerd acquisition has increased interest expense, which has been weighing upon the bottom-line. This has put the company at a competitive disadvantage relative to its competitors with less indebtedness.
Furthermore, Rite Aid's generic drug sales are negatively affected by Wal-Mart Stores Inc.'s (WMT) strategy of entering the retail generic drug market. Due to Wal-Mart's broad array of manufacturers in India, Israel, and the U.S., the mass merchant can offer generic drugs at a discounted price compared with the average $10 generic drug co-pay.
RITE AID CORP (RAD): Free Stock Analysis Report
WAL-MART STORES (WMT): Free Stock Analysis Report
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment